Getting a drug program into and through FDA review depends heavily on preparation. Two points in the development lifecycle carry particularly high risk: the Investigational New Drug (IND) application that allows clinical studies to begin and the marketing application (NDA or BLA) that seeks approval. At both stages, an incomplete or poorly organized submission can create delays. In the case of a marketing application, those gaps may lead to a Refuse to File (RTF) decision that sends a sponsor back to address deficiencies before review can even begin. Increasingly, organizations are treating readiness not as an administrative exercise, but as a critical component of regulatory risk management.
At PSC Biotech, we share that perspective. A submission is ultimately the visible outcome of months or years of quality, regulatory, and documentation work. When that foundation is strong, filing tends to move more smoothly. When it is not, weaknesses often become apparent at the most critical point in the program.
Below are the practices that contribute to stronger IND and marketing application submissions.
1. Requirements That Drive the Entire IND Package
A successful IND begins with a submission built around several core principles.
First, information should be traceable. Nonclinical results, CMC documentation, and the clinical protocol should support the same intended use and tell a consistent story. Safety considerations must also be addressed appropriately, with pharmacology and toxicology data aligned to the proposed risk of the study. Finally, the submission should be organized in a way that allows sections to be reviewed independently while remaining connected to the overall development strategy.
Strong IND packages go beyond checking every regulatory box. They present a clear, scientifically defensible rationale for why the proposed clinical trial can proceed safely. That is the central question FDA evaluates under 21 CFR Part 312.
2. Risk as the Organizing Principle
Risk assessment should guide every stage of IND preparation.
Some programs may have vulnerabilities within the CMC section that raise questions about manufacturing controls. Others may rely on toxicology data that does not clearly establish an adequate safety margin. In some cases, a protocol may leave endpoints or study design elements open to interpretation. Each of these issues has the potential to draw increased scrutiny from reviewers.
The advantage of identifying these weaknesses early is straightforward. Addressing deficiencies before submission is typically far less costly than responding after a clinical hold or major regulatory concern has already interrupted a development program.
3. Early FDA Interaction Where It Reduces Risk
A pre-IND meeting often provides one of the most valuable opportunities for reducing uncertainty.
These interactions allow sponsors to discuss study design, review manufacturing plans, and gain clarity around safety expectations before finalizing the submission package. Questions that might otherwise appear later as deficiencies can often be addressed through direct dialogue with the agency.
This approach helps transform assumptions into confirmed expectations. Rather than guessing what FDA reviewers want to see, sponsors can validate their strategy and make adjustments before significant resources are committed.
In many ways, this is one of the most efficient forms of risk management available during development.
4. A Filing Checklist to Prevent Refuse to File Decisions
The stakes become even higher once a program reaches the marketing application stage.
Under 21 CFR 314.101, FDA conducts an initial filing review within 60 days of receiving an application. During that process, the agency determines whether the submission is sufficiently complete to proceed into formal review. Applications that are incomplete or improperly organized may receive a Refuse to File decision.
For that reason, many organizations rely on structured filing checklists before submission. These reviews help confirm that:
- Required components are present for the application type and indication.
- Information is organized in the expected format.
- The application meets the minimum threshold for filing before FDA performs its own assessment.
An RTF can be costly in both time and resources. Timelines may slip, development plans may be disrupted, and expectations from investors or strategic partners can be affected. Conducting a thorough readiness review before submission is often the most effective way to avoid these issues.
5. CTD Format and Completeness
Submission success depends on both content and organization.
Most INDs, NDAs, and BLAs are prepared using the Common Technical Document (CTD) structure and submitted electronically through the eCTD framework. This standardized format helps regulators review information consistently across applications.
Each section serves a specific purpose:
- The Quality (CMC) module demonstrates control of the manufacturing process.
- The Nonclinical module provides evidence supporting the proposed use.
- The Clinical module presents study findings in a clear and consistent manner.
Even when the underlying science is strong, poor organization can slow reviews and create unnecessary questions. Presentation matters. A complete submission that is difficult to navigate may still face challenges during the review process.
6. How PSC Biotech Supports Submission Readiness
Organizations that consistently achieve successful submissions tend to follow similar practices. They prepare applications as risk-assessed packages, engage FDA when appropriate, maintain strong documentation practices, and verify completeness before filing.
PSC Biotech supports sponsors through:
- Regulatory strategy for IND and marketing application pathways
- CMC and quality documentation support
- CTD and eCTD submission preparation
- Filing-readiness assessments and checklist reviews before submission
These activities help reduce the likelihood of clinical holds, filing delays, and Refuse to File decisions while supporting program timelines.
Summary
A strong submission-readiness strategy is built on several key elements: identifying and managing risk early, engaging FDA at the right points in development, verifying completeness before filing, and maintaining disciplined CTD organization throughout the process.
When these practices come together, organizations place themselves in a stronger position for review. They reduce avoidable delays, improve regulatory interactions, and create a clearer path through both IND and marketing application milestones.
About PSC Biotech®
Founded in 1996, PSC Biotech® has spent 30 years providing life sciences with essential services to ensure that healthcare products are developed, manufactured, and distributed to the highest standards in compliance with all applicable regulatory requirements.
Our goal is to skyrocket our clients’ success. To achieve this, our method is straightforward; we put the client’s needs first. We attain top-tier expertise for each project stage, from generating comprehensive project plans to reaching extensive production operations into attentive asset management, authenticity, and non-expendable ventures.
Since our inception, PSC Biotech® has served as a strategic partner to emerging and established life science companies, all to help bring their life-saving products to market. PSC Biotech® operates in 52 countries globally and has served thousands of clients. Employing a global team of skilled professionals and experts that span strategically located offices in North America, Europe, Asia, the Middle East, and Australia, we are proud of the roles we have fulfilled to help our clients achieve success.
Explore PSC Biotech’s full range of services at biotech.com, and follow us on LinkedIn to stay up to date on everything PSC!
Regulatory References
- 21 CFR Part 312 (Investigational New Drug Application).
- 21 CFR Part 314, including 314.101 (filing and Refuse to File criteria for NDAs); parallel expectations apply to biologics license applications.
- ICH M4 (Common Technical Document / CTD structure); ICH M3 (nonclinical safety studies to support clinical trials); ICH E6 (Good Clinical Practice).
- FDA good review practice guidance, including criteria for refusing to file a marketing application.